Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations

Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC

NCT05011487 ·Status: RECRUITING ·Phase: PHASE2

Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC

NCT05009836 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT05168566 ·Status: RECRUITING ·Phase: PHASE2

Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification

NCT05015608 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study to Predict Gefitinib' s Efficacy for Lung Cancer by Plasma Free Nucleic Acids EGFR Gene Mutation Test

NCT02738684 ·Status: UNKNOWN

Jinfukang Oral Liquid Combined With Chemotherapy for Treating Driver Gene-negative Advanced NSCLC

NCT05098990 ·Status: UNKNOWN ·Phase: PHASE4

Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)

NCT03240393 ·Status: WITHDRAWN ·Phase: PHASE2

A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC

NCT06010329 ·Status: RECRUITING ·Phase: PHASE2

Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations

NCT05507606 ·Status: UNKNOWN ·Phase: PHASE2

Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC

NCT04322578 ·Status: RECRUITING ·Phase: PHASE2

Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC

NCT06688656 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)

NCT06015503 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC

NCT05997719 ·Status: RECRUITING

Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer

NCT05003037 ·Status: UNKNOWN ·Phase: PHASE2

Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer

NCT04685070 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

NCT06071013 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

NCT05104788 ·Status: RECRUITING ·Phase: PHASE2

Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer

NCT01951469 ·Status: UNKNOWN ·Phase: PHASE3

Salvage Surgery Following Downstaging of Advanced Non-small Cell Lung Cancer by Targeted Therapy (SDANT)

NCT05085054 ·Status: UNKNOWN ·Phase: PHASE2

Study of EGFR-TKI to Asymptomatic Brain Metastases of NSCLC

NCT02250846 ·Status: UNKNOWN ·Phase: PHASE2

Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients

NCT07143513 ·Status: COMPLETED

Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer

NCT07028489 ·Status: RECRUITING

High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC

NCT02960607 ·Status: UNKNOWN ·Phase: PHASE2

Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation

NCT05146219 ·Status: COMPLETED ·Phase: PHASE2

Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance

NCT02930954 ·Status: UNKNOWN ·Phase: PHASE2